At the San Antonio Breast Cancer Symposium (SABCS), investigators outlined the rationale and design of the ERADICATE, a first ...
BioArctic AB's (publ) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of Leqembi (lecanemab) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback